Introduction
============

Hereditary cancer syndrome means that inherited genetic mutations can increase a person's risk of developing cancer. Specifically, certain genetic mutations can cause changes in the growth control of normal cells and cause them to become cancerous. Genetic mutations that promote cancer can be inherited if the mutations are present in germ cells. It is reported that inherited genetic mutations play a major role in 5% to 10% of all cancers. The most well-known genes associated with hereditary cancer syndrome are the *BRCA1/2* genes for hereditary breast and ovarian cancer syndrome (HBOC) and the *TP53* gene for Li-Fraumeni syndrome. Approximately 7% of breast and 13% of ovarian cancers are estimated to be due primarily to germline mutations in the *BRCA1/2* genes. The cumulative risks of breast and ovarian cancers in *BRCA1/2* mutation carriers are reported to be 72% (95% confidence interval \[CI\], 65 to 79) and 44% (95% CI, 36 to 53), respectively, in *BRCA1* carriers and 69% (95% CI, 61 to 77) and 17% (95% CI, 11 to 25), respectively, in *BRCA2* carriers \[[@b1-crt-2019-559]\]. The cumulative cancer risk associated with *TP53* mutation may be as high as 90% by the age of 60 years \[[@b2-crt-2019-559]\]. In addition to mutations in *BRCA1/2* and *TP53*, germline mutations in certain genes were associated with more than 50 hereditary cancer syndromes. Genetic tests for hereditary cancer syndromes can identify individuals and families at increased risk of developing cancer. Once individuals or families are identified for hereditary cancer syndrome, they can be referred for risk assessment and personalized management that may include intensive cancer surveillance, risk-reducing surgery and genetic counseling.

With the rapid progress that has been made in next-generation sequencing (NGS) technology, simultaneous sequencing of multiple genes has become available through multiple-gene panel testing, which is less expensive and more rapid than single-gene testing. Furthermore, multiple-gene panels using NGS technology have increased the detection rate of mutations compared to conventional gene-bygene testing \[[@b3-crt-2019-559]\].

Currently, several commercial multiple-gene panels provide genetic information for hereditary cancer risk assessment. However, there are differences among ethnicities in cancer-susceptible germline mutations, and the assessment of germline mutations in all ethnic groups with clinical data is mandatory. In Korea and Asia, several studies evaluated the frequency of germline mutations, including *BRCA1/2* and/or other mutations associated with hereditary cancer syndrome. However, the results of most of the studies were not representative of the Korean and Asian population because of the relatively small number of patients included and the limited gene list evaluated.

In this study, we applied multiple-gene panel testing to 64 cancer susceptibility genes to examine the frequency of mutations and to assess the clinical value of NGS-based multiple-gene panel testing in breast cancer patients with clinical features of HBOC.

Materials and Methods
=====================

1. Patient selection
--------------------

The study population included breast cancer patients with the following features of HBOC: (1) diagnosed with breast cancer and another primary cancer; (2) a family history that included at least two cases of breast cancer in first- or second-degree relatives; (3) bilateral breast cancer; or (4) breast cancer diagnosis before the age of 40 years and with collected blood samples in tissue bank in Breast Care Center, Seoul National University Hospital, Korea and Breast Cancer Center, National Cancer Center, Korea (CONSORT diagram) ([S1 Fig.](#SD1-crt-2019-559){ref-type="supplementary-material"}) Of the patients, 349 patients were admitted to Seoul National University Hospital, Korea, and 147 patients were admitted to the National Cancer Center, Korea, between 2002 and 2017. All patients consented to multi-gene panel testing for clinical research. Blood samples of the included patients were collected from each hospital and sent to a central laboratory for sequencing. The medical records were reviewed, and personal and family histories and pathologic data of cancer were recorded.

2. NGS assay
------------

Genomic DNA was extracted from the participants' peripheral blood samples. Our panel included 64 hereditary cancer-predisposing genes (*ALK, APC, ATM, ATR, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FH, FLCN, GSTP1, HOXB13, KRAS, LIG4, MEN1, MET, MLH1, MRE11A, MSH2, MSH6, MUTYH, NAT1, NBN, NF1, PALB2, PALLD, PMS2, PRKAR1A, PRSS1, PTEN, RAD50, RAD51, RAD51C, RAD51D, RB1, RET, SDHB, SDHC, SDHD, SLX4, SMAD4, SPINK1, STK11, TP53, VHL*, and *XRCC2*) ([Table 1](#t1-crt-2019-559){ref-type="table"}). For mutation analysis, 64 gene-containing DNA fragments were enriched by solution-based hybridization capture and followed by sequencing with an Illumina NextSeq platform (Illumina, San Diego, CA) with the 150-bp paired-end read module. The target region included all coding exons. Capture probes were generated by Celemics, Inc. (Seoul, Korea). The hybridization capture procedure was also performed according to the manufacturer's standard protocol. Genomic DNA was sheared via sonication. Biotynilated RNA oligonucleotide probes were hybridized with sheared DNA. Captured fragments were removed from solution via streptavidin-coated magnetic beads and subsequently eluted. The enriched fragment library was then subjected to polymerase chain reaction (PCR) amplification using primers specific to the linked Illumina adaptors. Resulting libraries were quantified via Agilent 2200 TapeStation before proceeding to Illumina NextSeq platform. All samples were pooled into a single lane on a flow cell and sequenced together.

Raw FASTQ files were filtered using Trimmomatic ver. 0.33 and aligned with the genome of reference (GRCh37/hg19) using Burrows-Wheeler Aligner ver. 0.7.10. PCR duplicates, overrepresented sequences, and low-quality reads were removed. Realignments of insertions and deletions were performed using GATK. Reads with mapping quality of 0 were filtered out. If a read was able to be mapped at two different places with an identical percentage, the mapping quality equaled zero. Otherwise, the read was mapped to the most identical region. When ≥ 90% of mutation reads were biased to forward or reverse, this read was filtered out. The cutoff value of minimum supporting reads and minimum coverage was 2 and 8. The mean depth over target region was 660. The mean read size was 139 and mean uncovered ratio over target was 0.16%. Variant calling was performed with Samtools ver. 1.1 and Varscan ver. 2.4.0 ([S2 Table](#SD2-crt-2019-559){ref-type="supplementary-material"}).

3. Mutation analysis and variant classification
-----------------------------------------------

Variants were described according to the nomenclature recommendations of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>) and classified according to the following American College of Medical Genetics and Genomics recommendations: pathogenic (P), likely-pathogenic (LP), variants of unknown significance (VUS), likelybenign, and benign/polymorphism \[[@b4-crt-2019-559]\]. We used online databases, including the Human Gene Mutation Database, the Single Nucleotide Polymorphism Database, the 1000 Genome project, ClinVar, the Sorting Intolerant From Tolerant, Polymorphism Phenotyping-2, and the Korean Reference Genome Database, for *in silico* prediction of identified variants. Variants classified as P or LP were considered deleterious mutations.

4. Statistical analysis
-----------------------

Participant characteristics and sequencing results were summarized with descriptive statistics, which included medians, means, and standard deviations. The distributions of deleterious mutation according to the inclusion criteria were compared using Pearson's chi-square analysis and Student's t test. All p-values were 2-sided and a p-value less than 0.05 was considered significant. All statistical analyses were performed using IBM SPSS Statistics for Windows ver. 23.0 (IBM Corp., Armonk, NY).

5. Ethical statement
--------------------

This study was approved by the Institutional Review Board of the Seoul National University Hospital (No. 1509-132-689) and National Cancer Center (No. NCCNCS13717). All participants in this study provided consent to this research.

Results
=======

1. Study population
-------------------

The clinical characteristics of the patients are shown in [Table 2](#t2-crt-2019-559){ref-type="table"}. The median age at diagnosis of cancer was 48 years (range, 19 to 80 years). In these patients, 390 patients (78.6%) had stage I or II disease. More than half of the patients (n=250, 50.4%) had another primary cancer, including ovarian cancer, stomach cancer, colon cancer, lung cancer, or other malignancy. In all, 169 patients (34.1%) reported that they had two or more first- or second-degree relatives with breast cancer. Fifty-seven patients (11.5%) had synchronous or metachronous bilateral breast cancer, and 84 patients (16.9%) were diagnosed with breast cancer at an age younger than 40 years. Sixty-four patients had two or more risk factors for HBOC (e.g., bilateral breast cancer and breast cancer diagnosis \< 40 years old).

2. Frequency of deleterious mutations
-------------------------------------

[Table 2](#t2-crt-2019-559){ref-type="table"} summarizes the characteristics of patients with and without deleterious mutations. Of all 496 patients, 95 patients (19.2%) were found to have deleterious germline mutations of cancer susceptibility genes and 401 patients (80.8%) were not detected to carry deleterious mutations. The breast cancer stage was not different between the two groups (p=0.078). The proportions of risk factors, including breast cancer with another primary cancer, family history of breast cancer, and bilateral breast cancer were also not different between the groups. However, the proportion of patients with deleterious mutations were higher in patients who were diagnosed with breast cancer at younger than 40 years old than patients with another risk factors. Breast cancer diagnosis at young age was associated with a higher rate of deleterious mutations (p=0.022). Furthermore, having two or more risk factors for HBOC was also associated with a higher rate of deleterious mutations (p=0.001).

Breast cancers can be divided into four major subtypes depending on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status that have different clinical outcomes and responses to therapy a: luminal A (HR+ and HER2--), luminal B (HR+ and HER2+), HER2-enriched (HR-- and HER2+), and triple-negative (HR-- and HER2). [Table 3](#t3-crt-2019-559){ref-type="table"} showed the percentage of subtypes in 410 patients whose immunohistochemistry data were available. The percentage of patients with *BRCA1* mutations was different with patients without *BRCA1/2* mutations (p \< 0.001). Seventy-five percent of patients with *BRCA1* mutations were triple-negative breast cancer, whereas 20.8% of patients were HR (+) breast cancer including luminal A and luminal B subtypes. In contrast, the percentage of subtypes in *BRCA2* mutations was not statistically different with patients without *BRCA1/2* mutations (p=0.825).

[Table 4](#t4-crt-2019-559){ref-type="table"} and [Fig. 1](#f1-crt-2019-559){ref-type="fig"} summarize 48 deleterious mutations found in 95 patients. Of these patients with deleterious mutations, 60 patients (12.1%) had *BRCA1/2* mutations: 31 in *BRCA1* and 30 in *BRCA2*. Patients HOPE_309 and HOPE_502 had 2 *BRCA1* mutations and patient HOPE_57 carried both *BRCA1* and *BRCA2* mutations. In addition, 38 patients (7.7%) had cancer susceptibility gene mutations other than *BRCA1/2*: 35 patients had non-*BRCA1/2* mutations and three patients had both a *BRCA1/2* mutation and a non-*BRCA1/2* mutation (HOPE_14 had *BRCA2* and *SPINK1* mutations; HOPE_33 had *BRCA2*, *CDH1*, and *TP53* mutations; and HOPE_421 had *BRCA1* and *NBN* mutations). Most of the deleterious mutations were found in *CDH1* (n=8, 8.4%), *RAD51* (n=7, 7.4%), *SPINK1* (n=6, 6.3%), *TP53* (n=5, 5.3%) and *NBN* (n=3, 3.2%). The remaining patients had deleterious mutations in *CHEK2*, *FANCA*, *MLH1* (n=2 of each, 2.1%), *BRIP1*, *MRE11A*, *MSH2*, and *MUTYH* (n=1 of each, 1.1%).

The proportion of deleterious mutations varied according to risk factors. The deleterious mutations were found in 39 of 250 patients (15.6%) who had breast cancer and another primary cancer, 38 of 169 patients (22.5%) who had a family history (≥ 2 relatives) of breast cancer, 16 of 57 patients (28.1%) who had bilateral breast cancer, and 29 of 84 patients (34.5%) who were diagnosed with breast cancer at younger than 40 years old ([Fig. 2](#f2-crt-2019-559){ref-type="fig"}). Furthermore, the distributions of the cancer susceptibility genes were different according to risk factors ([Fig. 3](#f3-crt-2019-559){ref-type="fig"}). In breast cancer patients with another primary cancer, *BRCA1/2* and non-*BRCA1/2* mutations accounted for 52.3% and 47.7% of mutations, respectively. The non-*BRCA1/2* mutations comprised *CDH1* (11.4%), *SPINK1* (9.1%), *RAD51* (6.8%), and *TP53* (6.8%) mutations. In breast cancer patients with a family history of breast cancer, 65.8% carried a *BRCA1/2*mutation. In 34.2% of non-*BRCA1/2* mutations, 7.9% had *RAD51* and *TP53* mutations, and 5.3% had *CDH1* and *SPINK1* mutations. In bilateral breast cancer patients, 68.4% carried a *BRCA1/2* mutation. Among the 31.6% who had non-*BRCA1/2* mutations, *CHEK2* (10.5%) were found frequently and 5.3% of patients had *CDH1*, *TP53*, *NBN*, and *MRE11A* mutations. In patients diagnosed with breast cancer at younger than 40 years old, 62.1% carried *BRCA1/2* mutations and 37.9% carried non-*BRCA1/2* mutations including *RAD51*, *NBN*, *CHEK2*, *CDH1*, *TP53*, *PTEN*, *FANCA*, and *MRE11A* mutations.

In 64 hereditary cancer-predisposing genes, we found deleterious mutations in 16 genes, including *BRCA1/2*. However, we did not find deleterious mutations in the remaining 48 genes.

3. Novel deleterious mutations
------------------------------

We detected two novel deleterious mutations that were not previously reported: NM_000059.3:c.3096_3111del (p.Lys1032Asnfs\*6) in *BRCA2* and NM_000249.3:c.849T\>A (p.Tyr283\*) in *MLH1*. The NM_000059.3:c.3096_3111del in *BRCA2* is identified in patient HOPE_468. This mutation encodes a truncated non-functional protein in the domain of the BRC repeats, interfering with cellular response to DNA damage ([Fig. 4A](#f4-crt-2019-559){ref-type="fig"}). The NM_000249.3:c.849T\>A in *MLH1* is identified in patient HOPE_378 and is also predicted to encode a non-functional protein, leading to the disruption of an important functional domain, such as the MutL C-terminal domain ([Fig. 4B](#f4-crt-2019-559){ref-type="fig"}). The impact of both mutations were predicted deleterious mutations in *in silico* prediction.

4. Frequency of VUS
-------------------

A total of 333 missense mutations were identified in 64 genes. After *in silico* prediction by database and bioinformatics analysis to evaluate pathogenicity, most of the missense mutations were classified as benign or likely-benign. Mutations with conflicting interpretations of pathogenicity but suspicion of being deleterious were classified as VUS. A total of 20 VUS were identified in 67 patients (13.5%) ([Table 5](#t5-crt-2019-559){ref-type="table"}). In 15 patients, deleterious mutation and VUS were found concurrently. The proportion of VUS differed among the risk factors for HBOC ([Fig. 2](#f2-crt-2019-559){ref-type="fig"}). VUS was identified in 11.6% of breast cancer patients with another primary cancer, 14.8% of patients with a family history of breast cancer, 15.8% of bilateral breast cancer patients, and 17.0% of patients who were diagnosed with breast cancer younger than 40 years old. Additionally, 13 patients with VUS also had a concurrent deleterious mutation (HOPE_33, 66, 105, 115, 133, 182, 222, 233, 264, 280, 454, 468, and 501).

Discussion
==========

Patients who carry deleterious mutations are considered to be at high risk for developing cancer, and depending on the target organ, tailored surveillance programs or prophylactic risk-reducing surgery are recommended for decreasing cancer-related mortality. Currently, the National Comprehensive Cancer Network (NCCN) guidelines provide principles of genetic risk assessment and surveillance recommendations for various types of cancer. For example, women with *BRCA1/2* mutations are at high risk for breast and ovarian cancers and they are recommended to undergo magnetic resonance imaging (MRI) of the breast for screening and to discuss options for risk-reducing mastectomy or salphingooophorectomy.

We found that 19.2% of breast cancer patients who had clinical features of HBOC had deleterious mutations of cancer susceptibility genes. The breast cancer stage was not different between patients with and without deleterious mutations, nor were the proportions of risk factors for HBOC (breast cancer with another primary cancer, family history of breast cancer in two or more first- or second-degree relatives, and bilateral breast cancer). However, there was a significantly higher rate of patients who were diagnosed with breast cancer at an age younger than 40 years among deleterious mutation-positive patients (p=0.022) ([Table 2](#t2-crt-2019-559){ref-type="table"}, [Fig. 2](#f2-crt-2019-559){ref-type="fig"}). Furthermore, having two or more risk factors for HBOC was also associated with deleterious mutations (p=0.001).

Among 496 patients who were tested by the multiple-gene panel for cancer susceptibility genes, 60 patients (12.1%) were *BRCA1/2* positive, which was similar proportion to that reported in Western countries \[[@b5-crt-2019-559]\]. A previous study that included *BRCA1/2*-negative Korean breast cancer patients with features of hereditary breast cancer found that only 2.5% of non-*BRCA1/2* deleterious mutations were detected: *CHEK2* (0.4%), *PALB2* (0.9%), *MRE11* (0.4%), and *RAD50* (0.9%) \[[@b6-crt-2019-559]\]. Another study including Western patients reported that deleterious mutations were found only in 1.7% of 1994 familial breast cancer patients: *PALB2* (1.3%), *TP53* (0.3%), *CDH1* (0.05%), and *ATM* (0.05%) \[[@b7-crt-2019-559]\]. These studies reported that the frequency of deleterious mutations in each gene was less than 1% and concluded that a small portion of hereditary breast cancer was associated with non-*BRCA1/2* germline mutations. However, Li et al. \[[@b8-crt-2019-559]\] detected 11.5% non-*BRCA1/2* mutations, including *ATM, CDH1, CHEK2, PALB2, PTEN, STK11*, and *TP53* in 660 cases of familial breast cancer in a Western population. Ricker et al. \[[@b3-crt-2019-559]\] reported that multiple-gene panel testing increased the detection rate of deleterious mutations from 8.6% to 15.6% compared with a conventional gene-by-gene approach. Furthermore, they repor-ted that there were no significant differences in the mutation rates according to race or ethnic groups \[[@b3-crt-2019-559]\]. We identified 35 patients (8.0%) who had non-*BRCA1/2* deleterious mutations. These mutations included *CDH1* in seven patients (1.6%), *RAD51* in seven patients (1.6%), *SPINK1* in five patients (1.1%), and *TP53* in four patients (0.9%). The remaining patients had deleterious mutations in *CHEK2* (0.5%), *FANCA* (0.5%), *MLH1* (0.5%), *NBN* (0.5%), *BRIP1* (0.2%), *MRE11A* (0.2%), *MSH2* (0.2%), and *MUTYH* (0.2%). These results show that multiple-gene panel testing helps to increase the mutation detection rate compared to the conventional *BRCA* test alone. The results of previous studies and of our study are compatible with the suggestion of NCCN guidelines that multiple-gene testing may be more efficient and cost-effective for cancer risk assessment for patients with a high probability of hereditary cancer syndrome.

Germline *CDH1* mutations among the most frequently detected deleterious non-*BRCA1/2* mutations in our study. *CDH1* mutation is known to be associated with invasive lobular carcinoma and diffuse gastric cancer \[[@b9-crt-2019-559],[@b10-crt-2019-559]\]. The NCCN guidelines recommend that women with the *CDH1* mutation receive regular breast examinations with annual mammogram and breast MRI, as well as prophylactic total gastrectomy or regular esophagogastroduodenoscopy with multiple random biopsy. In this study, we found eight patients with *CDH1* mutation (NM_004360.4:c.2494G\>A), 7 patients with *CDH1* mutation only, and one patient (HOPE_33) with *CDH1* and another mutations (*BRCA2* NM_000059.3:c.3195_3198del and *TP53* NM_000546.5:c.566C\>T). Patient HOPE_33 carried *BRCA2*, *CDH1*, and *TP53* mutations; she developed bilateral breast cancer at 33 years of age. Two patients with only the *CDH1* mutation had a family history of breast cancer in two or more first- or second-degree relatives. Five patients with only the *CDH1* mutation had breast cancer with another primary cancer including leukemia (HOPE_23), stomach cancer (HOPE_28), colon cancer (HOPE_222), cervical cancer (HOPE_192), and thyroid cancer (HOPE_319). Patients with the *CDH1* mutation should have been recommended to receive close surveillance for contralateral breast cancer and stomach cancer. Further, family members of patient HOPE_28, who already had stomach cancer, should undergo genetic testing and receive close surveillance for breast and stomach cancers.

The *RAD51* gene has a key role in the repair of DNA double-strand breaks through homologous recombination \[[@b11-crt-2019-559]\]. Germline mutation of *RAD51* is known to cause congenital mirror movement which is characterized by involuntary movements of one side of the body that mirror intentional movements on the opposite side \[[@b12-crt-2019-559]\]. In addition to this congenital neurologic disorder, *RAD51* mutation is associated with the development of malignancy, in including breast cancer and pancreatic cancer \[[@b13-crt-2019-559],[@b14-crt-2019-559]\]. A previous study found that the proteins *BRCA2* and PALB2 control the function of *RAD51*, yielding structural change for cancer susceptibility \[[@b15-crt-2019-559]\]. In this study, we found eight patients with *RAD51* NM_002875.4:c.449G\>A. All patients with *RAD51* mutation were *BRCA1/2* negative. Three patients (HOPE_24, 35, and 335) had breast cancer and another primary cancer, including lung cancer, brain tumor, and thyroid cancer. Another three patients (HOPE_231, 324, and 418) had a family history of breast cancer in two or more relatives. One patient (HOPE_266) had breast cancer at an age younger than 40 years.

Germline mutation of *SPINK1* has been associated with hereditary pancreatitis by inhibiting the function of *SPINK1* protein and causing cellular damage by activated trypsin \[[@b16-crt-2019-559]\]. Several studies found that the *SPINK1* mutation was associated with pancreatic cancer \[[@b17-crt-2019-559]\]. In our study, 6 patients carried the deleterious *SPINK1* mutations (NM_003122.4:c.101A\>G). One patient (HOPE_14) had both breast cancer and pancreatic cancer and found to carry both *SPINK1* and *BRCA2* mutations (NM_000059.3:c.4092_4093del). Another three patients had breast cancer and an additional primary cancer, including stomach cancer, cervical cancer, and common bile duct cancer. The remaining two patients had a family history of breast cancer. However, *SPINK1* mutation is not rare despite of deleterious mutation. According to 1000 Genome Project Phase 3, allele frequency of this mutation is 0.003 in American, 0.008 in East Asian and 0.014 in South Asian. Because the allele frequency is relatively high in Asian population, this mutation is thought to have low penetrance in Asian population. Patient HOPE_14 who carried *SPINK1* and *BRCA2* mutations developed breast cancer in 2002 and pancreatic cancer in 2005. Considering that the *BRCA2*mutation is also known for increasing risk of pancreatic cancer and high minor allele frequency of *SPINK1* mutation (NM_003122.4:c.101A\>G), the main cause of breast and pancreatic cancer in patients HOPE_14 was *BRCA2* mutation, not *SPINK1* mutation \[[@b18-crt-2019-559]\].

Germline mutation of *TP53* is known as Li-Fraumeni syndrome. This mutation is associated with multiple cancers including breast cancer, soft tissue sarcoma, acute leukemia, brain tumor, adrenal carcinoma, and colon cancer. For this reason, Li-Fraumeni syndrome patients have a poor prognosis. Once this syndrome was revealed to be associated with a germline mutation of *TP53*, it became possible to detect carriers of inherited *TP53* mutations. Currently, individuals with a *TP53* mutation are recommended to undergo targeted surveillance, depending on individual medical history and family history. Villani et al. \[[@b19-crt-2019-559]\] reported that individuals with *TP53* mutation who received intensive surveillance with colonoscopy, whole body MRI, breast MRI, brain MRI, skin examination, and physical examination showed improved overall survival compared with individuals who did not receive surveillance (p=0.013). This result supports the effectiveness of a tailored surveillance program for increasing survival rates and is beneficial to individuals with deleterious mutations. In our study, five patients were identified to carry *TP53* mutations (NM_000546.5:c.566C\>T, NM_000546.5:c. 638G \>A, and NM_000546.5:c.743G\>A). As mentioned, HOPE_33 carried *BRCA2*, *CDH1*, and *TP53* mutations and had bilateral breast cancer at a young age. HOPE_395 and 396 carried *TP53* mutation (NM_000546.5:c.566C\>T) and suffered from breast cancer and thyroid cancer and had at least two relatives with a history of breast cancer. HOPE_290 had *TP53* mutation (NM_000546.5:c.638G\>A) and a family history of breast cancer in at least two relatives. HOPE_115 had *TP53* mutation (NM_000546.5:c.743G\>A) and had breast cancer and lung cancer. Family members of patients with *TP53* mutation need to undergo genetic testing to find out whether they are carriers of the *TP53* mutation or not. Depending on the results of genetic testing, *TP53* mutation carriers, as well as patients with *TP53* mutation, should consider clinical intensive surveillance for early detection of cancer and improved long-term survival.

Surveillance and risk-reducing strategies for patients with germline mutations of Lynch syndrome (*MLH1, MSH2, MSH6, PMS2*, and *EPCAM2*), such as colonoscopy, prophylactic hysterectomy, and bilateral salphingo-oophorectomy should be considered. In our study, three patients were found to have deleterious mutations in *MLH1* and *MSH2* (NM_000249.3: c.1758dup, NC_000003.11:c.849T\>A, and NM_000251. 2:c.229_230del). Patient HOPE_315 who carried *MLH1* mutation (NM_000249.3:c.1758dup) had primary breast, colon cancer, and lung cancer. Patient HOPE_394 who had *MSH2* mutations (NM_000251.2:c.229_230del) had primary breast and colon cancers. Patient HOPE_378 who carried novel deleterious mutation in *MLH1* (NM_000249.3:c.849T\>A) had breast cancer and hepatocellular carcinoma. Because Lynch syndrome is an inherited disorders that increases the risk of various type of cancer, particularly in colorectum, endometrium, ovary, stomach, small bowel, liver, bile duct, upper urinary tract, and brain, these three patients' family members should have intensive surveillance for colon cancer and genetic testing for germline mutations of Lynch syndrome.

It is well known that *BRCA1* and *BRCA2* mutation carriers showed differences in tumor histopathology. A large proportion of breast cancer in women who carry a *BRCA1* mutation exhibited a triple-negative breast cancer. Previous study including Korean familial breast cancer patients reported that triple-negative breast cancer was diagnosed in 57.1% of *BRCA1* mutation carriers \[[@b20-crt-2019-559]\]. In contrast with *BRCA1* mutations, luminal A and luminal B subtype of breast cancer was found in 83.0% in breast cancer patients who carried *BRCA2* mutations \[[@b21-crt-2019-559]\]. Our results showed that 75.0% of *BRCA1* mutation carriers were triple-negative breast cancer and 69.5% of *BRCA2* mutation carriers were HR-positive breast cancer including luminal A and B subtype, which are concordant with previous studies ([Table 3](#t3-crt-2019-559){ref-type="table"}).

The proportions and distributions of deleterious mutations in *BRCA1/2* negative patients were quite different in this Asian population than in a previously reported Western population. Maxwell et al. \[[@b22-crt-2019-559]\] reported that Caucasian and African American breast cancer patients who were *BRCA1/2* negative and had early-onset breast cancer (\< 40 years old at diagnosis) carried 11% of non-*BRCA1/2* deleterious mutations. The deleterious mutations were *ATM* (25.8%), *CHEK2* (32.3%), *TP53* (12.9%), and *MRE11A* (6.5%). The remaining mutations were *MSH6, CDKN2A, MUTYH, BARD1, BRIP1, NBN*, and *RAD50* (3.2%). The majority of deleterious mutations in our study in *BRCA1/2*-negative and early-onset breast cancer patients were *NBN* (30.0%), *RAD51* (20.0%), and *CHEK2* (20.0%) ([Fig. 3](#f3-crt-2019-559){ref-type="fig"}). Recently, Li et al. \[[@b23-crt-2019-559]\] reported the results of germline mutations among Chinese patients with features of hereditary breast cancer. They found that 16.9% of included patients carried *BRCA1/2* mutations and 6.8% of patients had non-*BRCA1/2* mutations including *TP53, PALB2, CHEK2, ATM, BARD1, BRIP, CDH1* and *RAD50*. Recent studies reported that mutations in *PALB2* and *RAD51C* were found to be an important cause of HBOC \[[@b24-crt-2019-559],[@b25-crt-2019-559]\]. Additionally, *CDH1* mutations were not found in the Western study but detected in the Chinese study. Although we did not find the *ATM, PALB2*, and *RAD51C* mutations in any of our study patients, we should have caution to interpret sequencing results of these important genes for HBOC.

We detected 2 novel deleterious mutations that have not been previously reported: NM_000059.3:c.3096_3111del (p.Lys1032Asnfs\*6) in *BRCA2* and NM_000249.3:c.849T\>A (p.Tyr283\*) in *MLH1*. The p.Lys1032Asnfs\*6 mutation in *BRCA2* was identified in patient HOPE_468. This mutation encodes a truncated non-functional protein in the domain of the BRC repeats ([Fig. 4A](#f4-crt-2019-559){ref-type="fig"}). The human tumor suppressor protein *BRCA2* plays a key role in recombinant DNA repair. *BRCA2* recruits *RAD51* to sites of DNA damage through interaction with eight conserved motifs of approximately 35 amino acids, the BRC repeats, although the specific function of each repeat remains unclear \[[@b26-crt-2019-559]\]. The mutation of *BRCA2* p.Lys1032Asnfs\*6 is thought to interfere with cellular response to DNA damage, resulting in malignant transformations. The p.Tyr283\* mutation in *MLH1* is found in patient HOPE_378 and is also predicted to encode a non-functional protein, leading to the disruption of important functional domain like MutL C-terminal domain ([Fig. 4B](#f4-crt-2019-559){ref-type="fig"}). The subunits of *MLH1* and PMS2 make the MutLα complex, which plays an essential role in mismatch repair \[[@b27-crt-2019-559]\]. A defect in *MLH1* is associated with mismatch repair and results in microsatellite instability and spontaneous mutation rate. The family history of patients with novel deleterious mutations and genetic tests of family members are required to determine the clinical impact of these newly identified mutations.

In this study, 67 patients (13.5%) were shown to have 20 VUS in 18 genes ([Table 5](#t5-crt-2019-559){ref-type="table"}). Compared with other studies, the rate of VUS in this study was relatively low. This could be because we excluded most of the missense mutations with conflicting interpretations and considered benign or likely-benign. We only considered mutations as VUS when mutations had conflicting interpretation of pathogenicity but a suspicion of being deleterious. Most of the VUS will be re-categorized as benign or deleterious. Until the significance is fully understood, VUS should not be used for making clinical decisions. It is also important to reduce the number of VUS in clinical practice. Potential deleterious mutations can be selected by mutation frequency analysis and *in silico* analysis. Recently, Findlay et al. \[[@b28-crt-2019-559]\] used saturation genome editing to assay single-nucleotide variants in exons that encode functional domains of BRCA1. They found that functional effects of saturation genome editing were almost perfectly concordant with established assessments of pathogenicity. The saturation genome editing will be useful for accurate classification of VUS in clinically actionable genes.

The application of multi-gene panel testing has been rapidly increasing in clinical practice, especially in the evaluation of germline mutations which are associated with cancer susceptibility. The identification of deleterious mutations in cancer susceptibility genes in individuals with a high risk for hereditary cancer can improve the effectiveness of personalized surveillance, leading to early detection or prophylactic treatment of hereditary cancer in both individuals and their family members. Intensive surveillance for early detection and prophylactic treatment is directly linked with better survival in patients with deleterious mutations.

However, there are limitations to multi-gene panel testing. The prevalence of pathogenic mutations and VUS vary across races and ethnicities. Furthermore, the penetrance and phenotype of mutations are different among individuals. Detection of a deleterious mutation does not always mean an individual will develop cancer, and conversely, a negative result from a multi-gene panel test does not mean an individual has no risk of getting cancer. Although two novel mutations were found to be pathogenic because of their functioning effect on protein level in *in silico* analysis, theses mutations were not clinically verified. Additional investigation including family history and targeted genetic tests of family members are required to determine the clinical impact of these newly identified mutations.

Another limitation is that we could not compare sequencing results between NGS and Sanger sequencing with same blood sample because of shortage of sample amount. The NGS-based multi-gene panel testing have weakness point in detecting mutations compared with Sanger sequencing including uncovered area, large insertion/deletion, and copy-number variation. Although these weaknesses can be overcame by technical improvement, clinical implication including long-term outcomes should be discussed carefully.

Last limitation is that the attitude and knowledge gaps of physicians who provide care for individuals who undergo genetic testing for a disease. One survey reported that, although most physicians received formal genetic education and agreed that genetic tests are clinically useful for assessing disease risk, they were not confident about interpreting test results and were not prepared for managing individuals at high risk for genetic disease. For these reasons, genetic education and genetic counseling, as well as the appropriate and accurate interpretation of results, are important for the effective clinical application of risk management strategies. Stadler et al. \[[@b29-crt-2019-559]\] proposed that the results of germline genetic testing using multi-gene panels, including cancer-related findings and other incidental findings, should be integrated with traditional risk assessments, such as personal and family histories, to establish cancer and non-cancer risk management and follow-up plans. The paradigm shift toward personalized and precision medicine requires the incorporation of NGS technologies into clinical practice.

To the best of our knowledge, this is the largest study to include Korean breast cancer patients with clinical features of HBOC and examine the frequency and characteristics of germline mutations in *BRCA1/2* and non-*BRCA1/2* cancer susceptibility genes.

We analyzed germline mutations from 496 breast cancer patients of Asian ethnicity with clinical features of HBOC using NGS-based multi-gene panel testing. Overall, 95 patients (19.2%) were found to carry 48 deleterious germline mutations in 16 cancer susceptibility genes. Of these 95 patients, 60 patients (63.2%) had *BRCA1/2*mutations, 38 patients (40.0%) had non-*BRCA1/2* mutations and three patients (3.2%) had both *BRCA1/2* and non-*BRCA1/2* mutations. The NGS-based multi-gene panel test improved the detection rates of deleterious mutations and provided a cost-effective cancer risk assessment compared with a gene-by-gene approach.
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Consort diagram for selecting patients

###### 

Summary statement of sequencing parametes

![Summary of 48 deleterious mutations in 95 patients. Deleterious *BRCA1* and *BRCA2* mutations were detected in 30 patiensts and 31 patients, respectively. Non-*BRCA1/2* germline mutations were found in 38 patients including *CDH1*, *RAD51*, *SPINK1*, *TP53* and so on.](crt-2019-559f1){#f1-crt-2019-559}

![The proportion of deleterious mutations according to risk factors of hereditary cancer syndrome. The highest proportion of deleterious mutations were found in breast cancer patients who were diagnosed at \< 40 years old and the lowest were found in breast cancer patient with another primary cancer. VUS, variants of unknown significance.](crt-2019-559f2){#f2-crt-2019-559}

![The distributions of the cancer susceptibility genes according to risk factors hereditary cancer syndrome. The proportion of *BRCA1/2* mutations were relatively small in breast cancer patients with another primary cancer compared with patients with other risk factors.](crt-2019-559f3){#f3-crt-2019-559}

![Novel deleterious mutations mapped on corresponding protein structures. The impact of mutatinos were predicted in *in silico* analysis. (A) NM_000059.3:c.3096_3111del (p.Lys1032Asnfs\*6) in *BRCA2*. (B) NM_000249.3:c.849T\>A (p.Tyr283\*) in *MLH1*.](crt-2019-559f4){#f4-crt-2019-559}

###### 

Hereditary cancer-predisposing genes in the multiple-gene panel test

  Gene        Breast   Ovarian   Colorectal   Endometrial   Gastric   Pancreatic   Melanoma   Prostate   Other
  ----------- -------- --------- ------------ ------------- --------- ------------ ---------- ---------- -------
  *ALK*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *APC*       \-       \-        O            \-            O         O            \-         \-         O
  *ATM*       O        \-        \-           \-            \-        O            \-         \-         \-
  *ATR*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *BAP1*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *BARD1*     O        \-        \-           \-            \-        \-           \-         \-         \-
  *BLM*       \-       \-        O            \-            \-        \-           \-         \-         O
  *BMPR1A*    \-       \-        O            \-            O         O            \-         \-         O
  *BRCA1*     O        O         \-           \-            \-        O            \-         O          \-
  *BRCA2*     O        O         \-           \-            \-        O            O          O          \-
  *BRIP1*     O        O         \-           \-            \-        \-           \-         \-         \-
  *CDH1*      O        \-        O            \-            O         \-           \-         \-         \-
  *CDK4*      \-       \-        \-           \-            \-        \-           O          \-         \-
  *CDKN2A*    \-       \-        \-           \-            \-        O            O          \-         \-
  *CHEK2*     O        \-        O            \-            \-        \-           \-         O          \-
  *EPCAM*     \-       O         O            O             O         O            \-         \-         O
  *FAM175A*   O        O         \-           \-            \-        \-           \-         \-         \-
  *FANCA*     O        \-        \-           \-            \-        \-           \-         \-         O
  *FANCB*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCC*     O        \-        \-           \-            \-        \-           \-         \-         O
  *FANCD2*    \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCE*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCF*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCG*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCI*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FANCL*     \-       \-        \-           \-            \-        \-           \-         \-         O
  *FH*        \-       \-        \-           \-            \-        \-           \-         \-         O
  *FLCN*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *GSTP1*     O        \-        \-           \-            \-        \-           \-         \-         O
  *HOXB13*    \-       \-        \-           \-            \-        \-           \-         O          \-
  *KRAS*      \-       \-        O            \-            O         O            O          \-         \-
  *LIG4*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *MEN1*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *MET*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *MLH1*      \-       O         O            O             O         O            \-         \-         O
  *MRE11A*    O        \-        \-           \-            \-        \-           \-         \-         \-
  *MSH2*      \-       O         O            O             O         O            \-         \-         O
  *MSH6*      \-       O         O            O             O         O            \-         \-         O
  *MUTYH*     \-       \-        O            \-            \-        \-           \-         \-         O
  *NAT*       \-       \-        O            \-            \-        \-           \-         \-         O
  *NBN*       O        \-        \-           \-            \-        \-           \-         O          \-
  *NF1*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *PALB2*     O        \-        \-           \-            \-        O            \-         \-         \-
  *PALLD*     \-       \-        \-           \-            \-        \-           \-         \-         \-
  *PMS2*      \-       O         O            O             O         O            \-         \-         O
  *PRKAR1A*   \-       \-        \-           \-            \-        \-           \-         \-         O
  *PRSS1*     \-       \-        \-           \-            O         O            \-         \-         \-
  *PTEN*      O        \-        O            O             \-        \-           \-         \-         O
  *RAD50*     O        O         \-           \-            \-        \-           \-         \-         \-
  *RAD51*     O        O         \-           \-            \-        \-           \-         \-         \-
  *RAD51C*    O        O         \-           \-            \-        \-           \-         \-         \-
  *RAD51D*    O        O         \-           \-            \-        \-           \-         \-         \-
  *RB1*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *RET*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *SDHB*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *SDHC*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *SDHD*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *SLX4*      \-       \-        \-           \-            \-        \-           \-         \-         O
  *SMAD4*     \-       \-        O            \-            O         O            \-         \-         O
  *SPINK1*    \-       \-        \-           \-            \-        \-           \-         \-         \-
  *STK11*     O        O         O            O             O         O            \-         \-         O
  *TP53*      O        O         O            O             O         O            O          O          O
  *VHL*       \-       \-        \-           \-            \-        \-           \-         \-         O
  *XRCC2*     O        \-        \-           \-            \-        \-           \-         \-         \-

###### 

Characteristics of patients with and without deleterious mutations

  Characteristic                                                             Total        No. deleterious mutation   Deleterious mutation   p-value (χ^2^)
  -------------------------------------------------------------------------- ------------ -------------------------- ---------------------- ------------------------------------------------------
  **No. of patients**                                                        496 (100)    401 (80.8)                 95 (19.2)              
  **Age at diagnosis, median (range, yr)**                                   48 (19-80)   49 (19-80)                 45 (22-72)             0.027^[a)](#tfn1-crt-2019-559){ref-type="table-fn"}^
  **Breast cancer stage**                                                                                                                   
   0                                                                         32 (6.5)     30 (7.5)                   2 (2.1)                0.078
   I                                                                         209 (42.1)   170 (42.4)                 39 (41.1)              
   II                                                                        181 (36.5)   138 (34.4)                 43 (45.3)              
   III                                                                       62 (12.5)    52 (13.0)                  10 (10.5)              
   IV                                                                        10 (2.0)     10 (2.5)                   0                      
   Unknown                                                                   2 (0.4)      1 (0.2)                    1 (1.1)                
  **Risk factors for HBOC^[a)](#tfn1-crt-2019-559){ref-type="table-fn"}^**                                                                  
   Breast cancer with another primary cancer                                 250 (50.4)   211 (52.6)                 39 (41.1)              0.052
   Family history of breast cancer (≥ 2 relatives)                           169 (34.1)   131 (32.7)                 38 (40.0)              0.187
   Bilateral breast cancer                                                   57 (11.5)    41 (10.2)                  16 (16.8)              0.075
   Breast cancer diagnosis at \< 40 yr                                       84 (16.9)    60 (15.0)                  29 (30.5)              0.022
   Two or more risk factors                                                  64 (12.9)    42 (10.5)                  22 (23.2)              0.002

Values are presented as number (%). HBOC, hereditary breast and ovarian cancer syndrome.

Statistical significance was evaluated by Student's t test.

###### 

The percentage of breast cancer subtypes according to *BRCA1/2* mutations

  Subtype           Patients without *BRCA1/2* mutations   Patients with *BRCA1* mutation   p-value (χ^2^)   Patients with *BRCA2* mutation   p-value (χ^2^)
  ----------------- -------------------------------------- -------------------------------- ---------------- -------------------------------- ----------------
  Luminal A         235 (64.6)                             5 (20.8)                         \< 0.001         15 (65.2)                        0.825
  Luminal B         32 (8.5)                               0                                                 1 (4.3)                          
  HER2-enriched     23 (6.3)                               1 (4.2)                                           1 (4.3)                          
  Triple-negative   75 (20.6)                              18 (75.0)                                         6 (26.1)                         

Values are presented as number (%). HER2, human epidermal growth factor receptor 2.

###### 

List of deleterious mutations identified in patients

  Gene                   Mutation                     Affected transcript          Affected protein     Case No.
  ---------------------- ---------------------------- ---------------------------- -------------------- ----------
  *BRCA1*                Frameshift insertion         NM_007294.3:c.3627dup        p.Glu1210Argfs\*9    HOPE_112
  HOPE_131                                                                                              
  HOPE_191                                                                                              
  HOPE_309                                                                                              
  HOPE_421                                                                                              
  HOPE_454                                                                                              
  HOPE_502                                                                                              
  Nonsense mutation      NM_007294.3:c.4981G\>T       p.Glu1661\*                  HOPE_287             
  Nonsense mutation      NM_007294.3:c.5080G\>T       p.Glu1694\*                  HOPE_11              
  HOPE_129                                                                                              
  HOPE_429                                                                                              
  HOPE_478                                                                                              
  Frameshift deletion    NM_007297.3:c.1575del        p.Glu525Aspfs\*16            HOPE_399             
  Frameshift deletion    NM_007294.3:c.1961del        p.Lys654Serfs\*47            HOPE_118             
  Missense mutation      NM_007294.3:c.5339T\>C       p.Leu1780Pro                 HOPE_226             
  HOPE_337                                                                                              
  HOPE_356                                                                                              
  Nonsense mutation      NM_007294.3:c.3991C\>T       p.Gln1331\*                  HOPE_57              
  Nonsense mutation      NM_007294.3:c.928C\>T        p.Gln310\*                   HOPE_10              
  HOPE_65                                                                                               
  Frameshift insertion   NM_007294.3:c.1511dup        p.Lys505\*                   HOPE_309             
  HOPE_502                                                                                              
  Frameshift deletion    NM_007294.3:c.923_924del     p.Ser308Lysfs\*11            HOPE_36              
  HOPE_270                                                                                              
  Frameshift deletion    NM_007294.3:c.3700_3704del   p.Val1234Glnfs\*8            HOPE_61              
  HOPE_351                                                                                              
  Nonsense mutation      NM_007294.3:c.5445G\>A       p.Trp1815\*                  HOPE_280             
  Nonsense mutation      NM_007294.3:c.390C\>A        p.Tyr130\*                   HOPE_72              
  HOPE_168                                                                                              
  HOPE_182                                                                                              
  HOPE_190                                                                                              
  HOPE_269                                                                                              
  Splice donor variant   NG_005905.2:c.5467+1G\>A     p.=                          HOPE_501             
  *BRCA2*                Frameshift deletion          NM_000059.3:c.700del         p.Ser234Profs\*7     HOPE_229
  Frameshift deletion    NM_000059.3:c.3096_3111del   p.Lys1032Asnfs\*6            HOPE_468 novel       
  Frameshift insertion   NM_000059.3:c.9253dup        p.Thr3085Asnfs\*26           HOPE_64              
  Missense mutation      NM_000059.3:c.8023A\>G       p.Ile2675Val                 HOPE_407             
  Nonsense mutation      NM_000059.3:c.1399A\>T       p.Lys467\*                   HOPE_57              
  HOPE_91                                                                                               
  HOPE_177                                                                                              
  HOPE_355                                                                                              
  Frameshift deletion    NM_000059.3:c.4092_4093del   p.Ile1364Metfs\*3            HOPE_14              
  Nonsense mutation      NM_000059.3:c.8140C\>T       p.Gln2714\*                  HOPE_456             
  Nonsense mutation      NM_000059.3:c.9076C\>T       p.Gln3026\*                  HOPE_465             
  Frameshift deletion    NM_000059.3:c.5576_5579del   p.Ile1859Lysfs\*3            HOPE_133             
  Nonsense mutation      NM_000059.3:c.7480C\>T       p.Arg2494\*                  HOPE_5               
  HOPE_31                                                                                               
  HOPE_80                                                                                               
  HOPE_114                                                                                              
  HOPE_307                                                                                              
  HOPE_345                                                                                              
  HOPE_389                                                                                              
  HOPE_479                                                                                              
  Frameshift deletion    NM_000059.3:c.2798_2799del   p.Thr933Argfs\*2             HOPE_350             
  Nonsense mutation      NM_000059.3:c.8951C\>G       p.Ser2984\*                  HOPE_359             
  Frameshift deletion    NM_000059.3:c.3195_3198del   p.Asn1066Leufs\*10           HOPE_33              
  HOPE_488                                                                                              
  Frameshift deletion    NM_000059.3:c.3744_3747del   p.Ser1248Argfs\*10           HOPE_158             
  HOPE_233                                                                                              
  HOPE_274                                                                                              
  HOPE_281                                                                                              
  HOPE_352                                                                                              
  Frameshift deletion    NM_000059.3:c.755_758del     p.Asp252Valfs\*24            HOPE_372             
  *BRIP1*                Nonsense mutation            NM_032043.2:c.2392C\>T       p.Arg798\*           HOPE_485
  *CDH1*                 Missense mutation            NM_004360.4:c.2494G\>A       p.Val832Met          HOPE_23
  HOPE_28                                                                                               
  HOPE_33                                                                                               
  HOPE_78                                                                                               
  HOPE_192                                                                                              
  HOPE_222                                                                                              
  HOPE_288                                                                                              
  HOPE_319                                                                                              
  *CHEK2*                Nonsense mutation            NM_007194.3:c.409C\>T        p.Arg137\*           HOPE_162
  Nonsense mutation      NM_001005735.1:c.1684C\>T    p.Arg562\*                   HOPE_310             
  *FANCA*                Frameshift deletion          NM_000135.3:c.3720_3724del   p.Glu1240Aspfs\*36   HOPE_125
  Frameshift deletion    NM_000135.2:c.2546del        p.Ser849Phefs\*40            HOPE_66              
  *MLH1*                 Frameshift insertion         NM_000249.3:c.1758dup        p.Met587Hisfs\*6     HOPE_315
  Nonsense mutation      NM_000249.3:c.849T\>A        p.Tyr283\*                   HOPE_378 novel       
  *MRE11A*               Missense mutation            NM_005591.3:c.140C\>T        p.Ala47Val           HOPE_285
  *MSH2*                 Frameshift deletion          NM_000251.2:c.229_230del     p.Ser77Cysfs\*4      HOPE_394
  *MUTYH*                Nonsense mutation            NM_001128425.1:c.55C\>T      p.Arg19\*            HOPE_225
  *NBN*                  Missense mutation            NM_002485.4:c.511A\>G        p.Ile171Val          HOPE_264
  HOPE_421                                                                                              
  HOPE_470                                                                                              
  *RAD51*                Missense mutation            NM_002875.4:c.449G\>A        p.Arg150Gln          HOPE_24
  HOPE_35                                                                                               
  HOPE_231                                                                                              
  HOPE_266                                                                                              
  HOPE_324                                                                                              
  HOPE_335                                                                                              
  HOPE_418                                                                                              
  *SPINK1*               Missense mutation            NM_003122.4:c.101A\>G        p.Asn34Ser           HOPE_14
  HOPE_105                                                                                              
  HOPE_144                                                                                              
  HOPE_179                                                                                              
  HOPE_413                                                                                              
  HOPE_497                                                                                              
  *TP53*                 Missense mutation            NM_000546.5:c.566C\>T        p.Ala189Val          HOPE_33
  HOPE_395                                                                                              
  HOPE_396                                                                                              
  Missense mutation      NM_000546.5:c.638G\>A        p.Arg213Gln                  HOPE_290             
  Missense mutation      NM_000546.5:c.743G\>A        p.Arg248Gln                  HOPE_115             

###### 

Variants of uncertain significance strongly suspected of being deleterious mutations

  Gene                Mutation                 Affected transcript         Affected protein   Case No.
  ------------------- ------------------------ --------------------------- ------------------ ----------
  *ALK*               Missense mutation        NM_004304.4:c.3260C\>T      p.Thr1087Ile       HOPE_163
  HOPE_264                                                                                    
  *ATR*               Missense mutation        NM_001184.3:c.3637A\>G      p.Ser1213Gly       HOPE_33
  HOPE_204                                                                                    
  *BLM*               Missense mutation        NM_000057.3:c.2371C\>T      p.Arg791Cys        HOPE_468
  HOPE_387                                                                                    
  HOPE_393                                                                                    
  *BRCA1*             Missense mutation        NM_007294.3:c.154C\>T       p.Leu52Phe         HOPE_79
  HOPE_105                                                                                    
  HOPE_187                                                                                    
  HOPE_232                                                                                    
  HOPE_233                                                                                    
  Missense mutation   NM_007294.3:c.3448C\>T   p.Pro1150Ser                HOPE_200           
  *BRCA2*             Missense mutation        NM_000059.3:c.7522G\>A      p.Gly2508Ser       HOPE_115
  HOPE_487                                                                                    
  HOPE_306                                                                                    
  *CDH1*              Missense mutation        NM_004360.4:c.1018A\>G      p.Thr340Ala        HOPE_124
  HOPE_133                                                                                    
  HOPE_218                                                                                    
  HOPE_436                                                                                    
  HOPE_476                                                                                    
  *CHEK2*             Missense mutation        NM_001005735.1:c.1240C\>T   p.His414Tyr        HOPE_164
  HOPE_242                                                                                    
  HOPE_466                                                                                    
  *FANCD2*            Missense mutation        NM_001018115.2:c.2480A\>C   p.Glu827Ala        HOPE_34
  HOPE_66                                                                                     
  HOPE_142                                                                                    
  HOPE_214                                                                                    
  HOPE_347                                                                                    
  HOPE_415                                                                                    
  *FANCD2*            Nonsense mutation        NM_001018115.1:c.1318C\>T   p.Gln440\*         HOPE_172
  *FANCE*             Missense mutation        NM_021922.2:c.991C\>G       p.Leu331Val        HOPE_26
  *FANCI*             Missense mutation        NM_001113378.1:c.1111A\>G   p.Ser371Gly        HOPE_25
  HOPE_86                                                                                     
  HOPE_113                                                                                    
  HOPE_164                                                                                    
  HOPE_202                                                                                    
  HOPE_217                                                                                    
  HOPE_246                                                                                    
  HOPE_280                                                                                    
  HOPE_342                                                                                    
  HOPE_468                                                                                    
  HOPE_501                                                                                    
  *FH*                Missense mutation        NM_000143.3:c.302G\>A       p.Arg101Gln        HOPE_145
  HOPE_182                                                                                    
  HOPE_198                                                                                    
  HOPE_439                                                                                    
  *LIG4*              Missense mutation        NM_001098268.1:c.2586T\>A   p.His862Gln        HOPE_182
  HOPE_291                                                                                    
  *MSH2*              Missense mutation        NM_000251.2:c.14C\>A        p.Pro5Gln          HOPE_186
  HOPE_209                                                                                    
  HOPE_222                                                                                    
  Missense mutation   NM_000251.2:c.1255C\>A   p.Gln419Lys                 HOPE_35            
  HOPE_88                                                                                     
  HOPE_98                                                                                     
  HOPE_232                                                                                    
  HOPE_237                                                                                    
  HOPE_414                                                                                    
  HOPE_435                                                                                    
  HOPE_454                                                                                    
  HOPE_462                                                                                    
  *MSH6*              Missense mutation        NM_000179.2:c.3772C\>G      p.Gln1258Glu       HOPE_144
  HOPE_442                                                                                    
  HOPE_490                                                                                    
  Missense mutation   NM_000179.2:c.2503C\>G   p.Gln835Glu                 HOPE_244           
  *PALB2*             Missense mutation        NM_024675.3:c.2509G\>A      p.Glu837Lys        HOPE_291
  HOPE_293                                                                                    
  HOPE_358                                                                                    
  *PTCH1*             Start lost               NM_001083603.2:c.1A\>G      p.Met1?            HOPE_89
  HOPE_463                                                                                    
  HOPE_481                                                                                    
  *TP53*              Missense mutation        NM_001126114.2:c.847C\>T    p.Arg283Cys        HOPE_187
